Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ 9,265,598	$ (42,265,674)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	13,100	13,100
Accretion of marketable securities premium	(86,774)	(661,830)
Amortization of right-of-use assets	118,487	106,600
Stock-based compensation expense	7,739,704	7,003,280
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(1,191,811)	529,112
Accounts payable	(1,615,419)	3,530,784
Accrued expenses and other current liabilities	396,747	2,588,818
Operating lease liabilities, current	(15,945)	31,631
Deferred revenue	(41,175,600)
Operating lease liabilities, noncurrent	(111,229)	(127,175)
Net cash used in operating activities	(26,663,142)	(29,251,354)
Cash flows from investing activities:
Proceeds from the maturity and redemption of marketable securities	28,400,000	65,845,000
Purchase of marketable securities	(3,871,706)	(49,447,545)
Net cash provided by investing activities	24,528,294	16,397,455
Cash flows from financing activities:
Proceeds from sales of common stock in public offering	12,550,069
Fees paid in connection with public offering	(455,666)
Proceeds from exercise of stock options	1,143,655	525,000
Net cash provided by financing activities	13,238,058	525,000
Net increase (decrease) in cash, cash equivalents and restricted cash	11,103,210	(12,328,899)
Cash, cash equivalents and restricted cash
Beginning of period	21,512,623	50,334,871
End of period	32,615,833	38,005,972
Reconciliation of the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets
Cash and cash equivalents	32,515,833	37,905,972
Restricted cash	100,000	100,000
Total cash, cash equivalents and restricted cash	$ 32,615,833	$ 38,005,972